Resmed Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.84 Intrinsic Value $316.64median of 6 methods · middle span $217-$348based on filings through 30 Jun 2026 Market Price $221.15Price as of 1 Oct 2026 UndervaluedIntrinsic value is 43% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $31.9B Enterprise Value $30.8B Shares Outstanding 146.1M diluted Moat Rating Wide Next Earnings Date29 Oct 2026 Last ex-dividend20 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Resmed combines a large connected-care ecosystem with sustained demand for sleep devices, masks and digital services. Fiscal 2026 ended with continued operating momentum, while portfolio simplification through the planned MatrixCare sale could sharpen investment around sleep, breathing and home-based care. The latest issuer-hosted NYSE quote was $240.33 on August 28, 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$175.00 Mean target$247.20 High · most bullish analyst$325.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $190.0020% Greater pharmaceutical substitution, a stronger competitive return by Philips, reimbursement pressure, product-safety costs or delays in the MatrixCare separation weaken growth expectations and push the shares toward the lower portion of their recent annual range. Base CaseCentral scenario $247.2055% Matches the consensus meanCore sleep and breathing demand remains positive, the connected-care ecosystem expands, and MatrixCare closes substantially as expected, but competition, reimbursement uncertainty and product-safety costs constrain valuation expansion. Bull CaseUpside scenario $290.0025% Broader sleep screening, continued AirSense and mask adoption, increasing use of AirView and myAir, successful commercialization of Noctrix's restless-legs therapy and a timely MatrixCare closing support stronger growth and a return toward the upper end of the recent annual trading range. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |